ID Week

Dr. Daniel Lucey provided insight on past and current yellow fever outbreaks and vaccine shortages at ID Week 2017; he also cited the very real possibility of yellow fever hitting Asia.

Amanda Paschke, MD, MSCE, explains the advantage of administering a beta-lactam in combination with a beta-lactamase inhibitor.

Results from a randomized, double-blind, placebo-controlled trial show that letermovir protects from viral infection in CMV-seropositive individuals following allogeneic hematopoietic cell transplantation.

Evelyn J. Ellis-Grosse, PhD, chief scientific officer of Zavante Therapeutics, explains why Zavante Therapeutic’s fosfomycin is a unique, novel antimicrobial.

The ambitious goal of global elimination of the virus by 2030 will take buy-in from all major stakeholders, including the United States.

Presenters combed through the barrage of clinical trials to share those that could be practice-changing for clinicians.

Christopher McCoy, PharmD, shares the protocol for approaching patients who may have a beta-lactam allergy.

Prolonged antibiotic use opens the door to the development of antibiotic resistance, superinfections, and the risk of Clostridium difficile infections.

The message for clinicians is to be vigilant. Look for candidemia and C. difficile infection occurring together.

Sue Cammarata, MD, explains the advantages that delafloxcin has over other fluoroquinolones.

Using combination antifungal therapy for invasive mold diseases is still a grey area that remains to be supported by robust data and relies heavily on clinician assessment.

Thoughts leaders believe infectious disease treatment is in the middle of a sea change, moving from antibiotics to antibodies.

Neil Fishman, MD, explains what the standardized antimicrobial administration ratio is.

Researchers found that the use of the treatment algorithm for staphylococcal bacteremia shortens therapy without compromising outcomes.

Emily Heil, PharmD, BCPS-AQ ID, sheds light on one of the standards of new antibiotic stewardship regulations: all antibiotic orders should include indication for use.

Whether the oft-repeated pattern of initial drug success followed by increasing resistance plays out in the future for many drugs remains to be seen.

David Andes, MD, shares the half-life and dosing intervals for a new long-acting echinocandin.

About 500,000 Americans fall ill from Clostridium difficile infections every year.

Dr. Maria Bye, an epidemiologist at the Minnesota Department of Health shares some unsettling news when it comes to C. difficile: dentists’ prescribing habits may be contributing to CDI incidence.

David Huang, PhD, MD, shares the recent results of the REVIVE-2 trial.

Candidemia is the most common healthcare-associated bloodstream infection in the United States, with an incidence of 5-15 per 100,000 persons.

Patrick Horn, MD, PhD, explains why eravacycline is a unique antibiotic and how it stands up against many different types of pathogens, including those that are multidrug-resistant.

It is only a matter of time before the next infectious disease pandemic hits and healthcare officials need to be prepared.

Dr. Monique Foster, CDC, and Dr. Eric McDonald, San Diego County Health and Human Services Agency, discuss the surprising return of hepatitis A virus as part of the Late Breakers I symposium.

James S. Lewis, PharmD, FIDSA, addresses the issues that surround current antibiotic development.

Contagion® will be providing exclusive coverage on the conference, and so, keep your eyes peeled for session coverage and interviews with some of the key presenters.

Madeline King, PharmD, assistant professor of Clinical Pharmacy at the University of the Sciences, Philadelphia College of Pharmacy in Philadelphia, Pennsylvania, explains how her future research aims to understand the effects of ceftazidime-avibactam in different patient populations.

Madeline King, PharmD, assistant professor of Clinical Pharmacy at the University of the Sciences, Philadelphia College of Pharmacy in Philadelphia, Pennsylvania, discusses the significance of the findings of her research on Ceftazidime-Avibactam.

Madeline King, PharmD, assistant professor of Clinical Pharmacy at the University of the Sciences, Philadelphia College of Pharmacy in Philadelphia, Pennsylvania, discusses her findings regarding patients treated with ceftazidime-avibactam for carbapenem-resistant Enterobacteriaceae infections and carbapenem-resistant Pseudomonas infections.

Madeline King, PharmD, assistant professor of Clinical Pharmacy at the University of the Sciences, Philadelphia College of Pharmacy in Philadelphia, Pennsylvania, discusses her research on the efficacy of ceftazidime-avibactam against infections caused by gram-negative organisms.